The latest price target for Aethlon Medical (NASDAQ:AEMD) was reported by HC Wainwright & Co. on August 14, 2025. The analyst firm set a price target for $1.50 expecting AEMD to fall to within 12 months (a possible -31.51% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Aethlon Medical (NASDAQ:AEMD) was provided by HC Wainwright & Co., and Aethlon Medical reiterated their neutral rating.

There is no last upgrade for Aethlon Medical

There is no last downgrade for Aethlon Medical.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aethlon Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aethlon Medical was filed on August 14, 2025 so you should expect the next rating to be made available sometime around August 14, 2026.

While ratings are subjective and will change, the latest Aethlon Medical (AEMD) rating was a reiterated with a price target of $1.50 to $1.50. The current price Aethlon Medical (AEMD) is trading at is $2.19, which is out of the analyst’s predicted range.